LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

Search

Crinetics Pharmaceuticals Inc

Closed

SectorHealthcare

32.42 -6.03

Overview

Share price change

24h

Current

Min

32.26

Max

34.15

Key metrics

By Trading Economics

Income

-5M

-128M

Sales

6.8M

11M

EPS

-1.23

Profit margin

-1,191.029

Employees

594

EBITDA

-18M

-139M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+155.33% upside

Dividends

By Dow Jones

Next Earnings

6 Aug 2026

Market Stats

By TradingEconomics

Market Cap

-469M

3.9B

Previous open

38.45

Previous close

32.42

News Sentiment

By Acuity

87%

13%

310 / 344 Healthcare

Crinetics Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

2 Jun 2026, 20:30 UTC

Earnings

Palo Alto Networks 3Q Revenue Rises as Customers Beef Up Cyber Defenses

2 Jun 2026, 23:58 UTC

Market Talk

Australia's Consumer Sector Expected to Be Stung by Housing Downturn -- Market Talk

2 Jun 2026, 23:46 UTC

Market Talk

Global Equities Roundup: Market Talk

2 Jun 2026, 23:46 UTC

Market Talk

Nikkei May Rise as AI Demand Hopes Continue -- Market Talk

2 Jun 2026, 23:41 UTC

Market Talk

Oil Rises Amid Signs of U.S.-Iran Peace Talks Stalling -- Market Talk

2 Jun 2026, 23:01 UTC

Acquisitions, Mergers, Takeovers

ACCC Says Owner of Metro Petroleum Brand to Buy the 41 Sites

2 Jun 2026, 23:01 UTC

Acquisitions, Mergers, Takeovers

ACCC Says Ampol Must Sell 41 Retail Fuel Sites to an Approved Purchaser

2 Jun 2026, 23:00 UTC

Acquisitions, Mergers, Takeovers

Australia's Competition Regulator Approves Ampol's Purchase of EG Australia With Conditions

2 Jun 2026, 22:57 UTC

Market Talk

Australian Dollar Could Fall Following 1Q GDP Data -- Market Talk

2 Jun 2026, 22:50 UTC

Market Talk

Ulta Beauty Says TikTok Shop Will Provide 'Halo' Effect -- Market Talk

2 Jun 2026, 21:07 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

2 Jun 2026, 21:07 UTC

Market Talk

Tokenized Assets Need Access to Digital-Finance Plumbing -- Market Talk

2 Jun 2026, 21:00 UTC

Earnings

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 Jun 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

2 Jun 2026, 20:46 UTC

Earnings

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 Jun 2026, 20:38 UTC

Earnings

GitLab Stock Rises as the Software Company Raises Guidance on AI Business Momentum -- Barrons.com

2 Jun 2026, 20:21 UTC

Earnings

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 Jun 2026, 20:12 UTC

Earnings

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 Jun 2026, 20:05 UTC

Earnings

Palo Alto Networks 3Q Product Rev $594M

2 Jun 2026, 20:05 UTC

Earnings

Palo Alto Networks Sees FY26 Next-Generation Security ARR $8.9B-$8.95B

2 Jun 2026, 20:05 UTC

Earnings

Palo Alto Networks Raises FY26 View To Adj EPS $3.77-Adj EPS $3.79 >PANW

2 Jun 2026, 20:05 UTC

Earnings

Palo Alto Networks 3Q Subscription and Support Rev $2.41B

2 Jun 2026, 20:05 UTC

Earnings

Palo Alto Networks Sees FY26 Remaining Performance Obligation $20.9B-$21B

2 Jun 2026, 20:05 UTC

Earnings

Palo Alto Networks Sees 4Q Rev $3.345B-$3.355B >PANW

2 Jun 2026, 20:05 UTC

Earnings

Palo Alto Networks Sees 4Q Adj EPS 96c-Adj EPS 98c >PANW

2 Jun 2026, 20:05 UTC

Earnings

Palo Alto Networks on Track to Achieve 40% Adj Free Cash Flow Margin in FY28

2 Jun 2026, 20:05 UTC

Earnings

Palo Alto Networks Raises FY26 View To Rev $11.415B-$11.425B >PANW

2 Jun 2026, 20:05 UTC

Earnings

Palo Alto Networks 3Q Remaining Performance Obligation $18.4B

2 Jun 2026, 20:05 UTC

Earnings

Palo Alto Networks 3Q Adj EPS 85c >PANW

2 Jun 2026, 20:05 UTC

Earnings

Palo Alto Networks 3Q Loss $177M >PANW

Peer Comparison

Price change

Crinetics Pharmaceuticals Inc Forecast

Price Target

By TipRanks

155.33% upside

12 Months Forecast

Average 88.14 USD  155.33%

High 97 USD

Low 81 USD

Based on 8 Wall Street analysts offering 12 month price targets forCrinetics Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

8 ratings

8

Buy

0

Hold

0

Sell

Sentiment

By Acuity

310 / 344 Healthcare

News Sentiment

Very Strong Bearish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
help-icon Live chat